In my previous article, I discussed how AI is rapidly transforming the drug discovery process, significantly accelerating timelines and reducing costs. However, while AI's potential in this domain is ...

As pipelines across modalities diversify, regulatory scrutiny intensifies, and the margin for error in development execution continues to shrink, partnering with a CDMO has never been more critical.

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study) The following represents ...

Many drugs still fail after promising preclinical results, raising difficult questions about how disease is modelled in the ...

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

The US Food and Drug Administration (FDA) this week released a new draft guidance on the development of new drugs intended to treat pulmonary tuberculosis (TB), a bacterially-transmitted disease that ...

While rare disease research has advanced significantly, related expertise and data are scattered across too many disconnected places.

Traws Pharma (NASDAQ:TRAW) shares fell sharply in premarket trading on Monday after the company revealed that UK regulators ...